Maria A Cebrià I Iranzo1,2,3, Anna Arnal-Gómez1,4, Maria A Tortosa-Chuliá5,6, Mercè Balasch-Bernat1,3, Silvia Forcano2, Trinidad Sentandreu-Mañó1,7, Jose M Tomas7,8, Natalia Cezón-Serrano1,3. 1. Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain. 2. Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain. 3. Physiotherapy in Motion, MultiSpeciality Research Group (PTinMOTION), University of Valencia, 46010 Valencia, Spain. 4. Research Unit in Clinical Biomechanics (UBIC), University of Valencia, 46010 Valencia, Spain. 5. Department of Applied Economics, University of Valencia, 46022 Valencia, Spain. 6. Psychological Development, Health and Society (PSDEHESO), University of Valencia, 46022 Valencia, Spain. 7. Advanced Research Methods Applied to Quality of Life Promotion (ARMAQoL), University of Valencia, 46010 Valencia, Spain. 8. Department of Methodology for the Behavioural Sciences, University of Valencia, 46010 Valencia, Spain.
Abstract
BACKGROUND: Recently, the European Working Group on Sarcopenia in Older People (EWGSOP2) has updated the sarcopenia definition based on objective evaluation of muscle strength, mass and physical performance. The aim of this study was to analyse the relationship between sarcopenia and clinical aspects such as functionality, comorbidity, polypharmacy, hospitalisations and falls in order to support sarcopenia screening in institutionalised older adults, as well as to estimate the prevalence of sarcopenia in this population using the EWGSOP2 new algorithm. METHODS: A multicentre cross-sectional study was conducted on institutionalised older adults (n = 132, 77.7% female, mean age 82 years). Application of the EWGSOP2 algorithm consisted of the SARC-F questionnaire, handgrip strength (HG), appendicular skeletal muscle mass index (ASMI) and Short Physical Performance Battery (SPPB). Clinical study variables were: Barthel Index (BI), Abbreviated Charlson's Comorbidity Index (ACCI), number of medications, hospital stays and falls. RESULTS: Age, BI and ACCI were shown to be predictors of the EWGSOP2 sarcopenia definition (Nagelkerke's R-square = 0.34), highlighting the ACCI. Sarcopenia was more prevalent in older adults aged over 85 (p = 0.005), but no differences were found according to gender (p = 0.512). CONCLUSION: BI and the ACCI can be considered predictors that guide healthcare professionals in early sarcopenia identification and therapeutic approach.
BACKGROUND: Recently, the European Working Group on Sarcopenia in Older People (EWGSOP2) has updated the sarcopenia definition based on objective evaluation of muscle strength, mass and physical performance. The aim of this study was to analyse the relationship between sarcopenia and clinical aspects such as functionality, comorbidity, polypharmacy, hospitalisations and falls in order to support sarcopenia screening in institutionalised older adults, as well as to estimate the prevalence of sarcopenia in this population using the EWGSOP2 new algorithm. METHODS: A multicentre cross-sectional study was conducted on institutionalised older adults (n = 132, 77.7% female, mean age 82 years). Application of the EWGSOP2 algorithm consisted of the SARC-F questionnaire, handgrip strength (HG), appendicular skeletal muscle mass index (ASMI) and Short Physical Performance Battery (SPPB). Clinical study variables were: Barthel Index (BI), Abbreviated Charlson's Comorbidity Index (ACCI), number of medications, hospital stays and falls. RESULTS: Age, BI and ACCI were shown to be predictors of the EWGSOP2 sarcopenia definition (Nagelkerke's R-square = 0.34), highlighting the ACCI. Sarcopenia was more prevalent in older adults aged over 85 (p = 0.005), but no differences were found according to gender (p = 0.512). CONCLUSION: BI and the ACCI can be considered predictors that guide healthcare professionals in early sarcopenia identification and therapeutic approach.
Authors: Carlos Guillamón-Escudero; Angela Diago-Galmés; Jose M Tenías-Burillo; Jose M Soriano; Julio J Fernández-Garrido Journal: Int J Environ Res Public Health Date: 2020-12-07 Impact factor: 3.390